Recent Updates
Recently added Catalysts
XENE Positive Sentiment Score: 70/100

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Tuesday, February 25, 2025 1 min read
Key Takeaway: Xenon Pharmaceuticals Inc. has announced its participation in the upcoming 45th Annual TD Cowen Healthcare Conference in Boston, scheduled for March 3-5, 2025. The presentation will take place on March 4, 2025, at 10:30 AM Eastern Time, featuring CEO Ian Mortimer and CFO Sherry Aulin. A live audio webcast will be available on the company's website, with replays to follow after the event. Xenon continues to advance its innovative therapies targeting unmet medical needs in neuroscience.

Market Sentiment Analysis

POSITIVE FACTORS

  • Xenon is scheduled to present at a major healthcare conference.
  • The company's focus on discovering life-changing therapeutics signifies a commitment to addressing significant medical needs.
  • Azetukalner, a novel potassium channel opener, is in late-stage clinical development, highlighting progress in their product portfolio.

Full Press Release Details

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.
Fireside Chat Presentation Details:
Date : Tuesday, March 4, 2025
Time : 10:30-11:00 AM Eastern Time
Webcast : Register here
Presenters : Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Vice President, Investor Relations
investors@xenon-pharma.com
Senior Vice President, Corporate Affairs
media@xenon-pharma.com

Frequently Asked Questions

When is Xenon Pharmaceuticals presenting at the TD Cowen Conference?

Xenon Pharmaceuticals will present on March 4, 2025.

Who will present at the 45th Annual TD Cowen Healthcare Conference?

Ian Mortimer and Sherry Aulin will represent Xenon Pharmaceuticals.

What is Azetukalner developed for?

Azetukalner is being developed for conditions like epilepsy and depression.

Where can I watch the Xenon Pharmaceuticals presentation?

The presentation will be accessible via a live webcast on their website.

What type of company is Xenon Pharmaceuticals?

Xenon is a biopharmaceutical company focused on neuroscience therapeutics.

Tags: XENE Viatris Investor Conferences Healthcare Xenon Pharmaceuticals td cowen healthcare conference neuroscience Azetukalner
Last updated: Feb 25, 2025